Sangamo Therapeutics Stock In The News

SGMO Stock  USD 0.51  0.03  6.25%   
Our overall analysis of Sangamo Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Sangamo Therapeutics. The specific impact of Sangamo Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Sangamo Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Sangamo Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Sangamo Therapeutics Backtesting and Sangamo Therapeutics Hype Analysis.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

Sangamo Therapeutics Today Top News and Investor Outlook

Yahoo News
H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data
https://finance.yahoo.com/news/h-c-wainwright-reaffirms-buy-131845867.html
 Bullish
Investing News at Macroaxis
Sangamo stock holds Buy rating at H.C. Wainwright on Fabry therapy data
https://www.investing.com/news/stock-market-news/sangamo-stock-holds-buy-rating-at-hc-wainwright-on-fabry-therapy-data-93CH-4110217
 Bullish
seekingalpha News
Sangamo rises after trial data for Fabry disease therapy
https://seekingalpha.com/news/4461536-sangamo-stock-rises-fabry-disease-data?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Bullish
nasdaq News
Sangamo Therapeutics Reports Positive Data From Phase 1/2 STAAR Study In Fabry Disease
https://www.nasdaq.com/articles/sangamo-therapeutics-reports-positive-data-phase-1-2-staar-study-fabry-disease
 Bullish
Investing News at Macroaxis
Sangamo reports positive results for Fabry disease gene therapy
https://www.investing.com/news/company-news/sangamo-reports-positive-results-for-fabry-disease-gene-therapy-93CH-4107866
 Bullish
Yahoo News
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...
https://finance.yahoo.com/news/sangamo-therapeutics-inc-sgmo-q1-170101803.html
 Bullish
Yahoo News
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
https://finance.yahoo.com/news/sangamo-therapeutics-sgmo-may-report-140141662.html
 Bullish
Yahoo News
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
https://finance.yahoo.com/news/pfizer-discontinues-hemophilia-gene-therapy-173546804.html
 Bullish
Yahoo News
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
https://finance.yahoo.com/news/sangamo-therapeutics-stock-plunges-pfizer-141419830.html
 Bullish
Yahoo News
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
https://finance.yahoo.com/news/astellas-sangamo-therapeutics-announce-capsid-073000159.html
 Bullish

Sangamo Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Sangamo and other traded companies coverage with news coverage. We help investors stay connected with Sangamo headlines for the 21st of July to make an informed investment decision based on correlating the impacts of news items on Sangamo Stock performance. Please note that trading solely based on the Sangamo Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Sangamo Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Sangamo Therapeutics investors visualize upcoming and past events in order to time the market based on Sangamo Therapeutics noise-free hype analysis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sangamo Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sangamo Therapeutics' short interest history, or implied volatility extrapolated from Sangamo Therapeutics options trading.
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:
Check out Sangamo Therapeutics Backtesting and Sangamo Therapeutics Hype Analysis.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.36)
Revenue Per Share
0.301
Quarterly Revenue Growth
12.383
Return On Assets
(0.47)
Return On Equity
(2.58)
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.